LabGenomics Participates in Obstetrics and Gynecology Autumn Conference... "Introducing New Products"

LabGenomics announced on the 23rd that it participated in the 16th Autumn Academic Conference of the Direct Election Korean Society of Obstetrics and Gynecology Practitioners held on the 22nd at the Seoul Swiss Grand Hotel Convention Center. The company introduced new prenatal anomaly screening services such as next-generation sequencing (NGS) MomGuard and EnfantGuardTM2.0 to obstetrics and gynecology specialists through its promotional booth.

Since 2015, LabGenomics has been the first in the industry to launch and provide non-invasive prenatal anomaly screening tests. The company offers services including chromosomal abnormality screening related to neonatal developmental disorders and hereditary metabolic disease screening. This enables genetic testing from prenatal anomaly screening to postnatal newborn testing.

In particular, this diagnostic service provides test results such as pathogenic variant status and chromosomal abnormality screening. It has the advantage of enabling early diagnosis of genetic diseases that are difficult to diagnose initially, leading to accurate treatment.

A LabGenomics representative stated, “We directly introduced MomGuard, EnfantGuard, and I’m Plus to medical staff at this academic conference and received a great response. We plan to continue participating in various academic conferences and expand our marketing activities.”

Meanwhile, LabGenomics is also preparing for the certification of in vitro diagnostic medical devices for an upgraded version of the existing MomGuard product and a PCR (polymerase chain reaction) kit related to Alzheimer’s dementia. In September, the company newly launched two PCR kits for diagnosing ankylosing spondylitis and Beh?et’s disease.

This content was produced with the assistance of AI translation services.